Preclinical evaluation of 18F-PSMA-1007, a new prostate-specific membrane antigen ligand for prostate cancer imaging
In recent years, several radiotracers targeting the prostate-specific membrane antigen (PSMA) have been introduced. Some of them have had a high clinical impact on the treatment of patients with prostate cancer. However, the number of 18F-labeled tracers addressing PSMA is still limited. Therefore,...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2017
|
| In: |
Journal of nuclear medicine
Year: 2016, Jahrgang: 58, Heft: 3, Pages: 425-431 |
| ISSN: | 2159-662X |
| DOI: | 10.2967/jnumed.116.181768 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.2967/jnumed.116.181768 Verlag, kostenfrei, Volltext: http://jnm.snmjournals.org/content/58/3/425 
|
| Verfasserangaben: | Jens Cardinale, Martin Schäfer, Martina Benešová, Ulrike Bauder-Wüst, Karin Leotta, Matthias Eder, Oliver C. Neels, Uwe Haberkorn, Frederik L. Giesel, Klaus Kopka |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1572238658 | ||
| 003 | DE-627 | ||
| 005 | 20230426124251.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180423r20172016xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2967/jnumed.116.181768 |2 doi | |
| 035 | |a (DE-627)1572238658 | ||
| 035 | |a (DE-576)502238658 | ||
| 035 | |a (DE-599)BSZ502238658 | ||
| 035 | |a (OCoLC)1341007467 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Cardinale, Jens |d 1981- |e VerfasserIn |0 (DE-588)1030356505 |0 (DE-627)735121206 |0 (DE-576)378165941 |4 aut | |
| 245 | 1 | 0 | |a Preclinical evaluation of 18F-PSMA-1007, a new prostate-specific membrane antigen ligand for prostate cancer imaging |c Jens Cardinale, Martin Schäfer, Martina Benešová, Ulrike Bauder-Wüst, Karin Leotta, Matthias Eder, Oliver C. Neels, Uwe Haberkorn, Frederik L. Giesel, Klaus Kopka |
| 264 | 1 | |c 2017 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published online: October 27, 2016 | ||
| 500 | |a Gesehen am 23.04.2018 | ||
| 520 | |a In recent years, several radiotracers targeting the prostate-specific membrane antigen (PSMA) have been introduced. Some of them have had a high clinical impact on the treatment of patients with prostate cancer. However, the number of 18F-labeled tracers addressing PSMA is still limited. Therefore, we aimed to develop a radiofluorinated molecule resembling the structure of therapeutic PSMA-617. Methods: The nonradioactive reference compound PSMA-1007 and the precursor were produced by solid-phase chemistry. The radioligand 18F-PSMA-1007 was produced by a 2-step procedure with the prosthetic group 6-18F-fluoronicotinic acid 2,3,5,6-tetrafluorophenyl ester. The binding affinity of the ligand for PSMA and its internalization properties were evaluated in vitro with PSMA-positive LNCaP (lymph node carcinoma of the prostate) cells. Further, organ distribution studies were performed with mice bearing LNCaP and PC-3 (prostate cancer cell line; PSMA-negative) tumors. Finally, small-animal PET imaging of an LNCaP tumor-bearing mouse was performed. Results: The identified ligand had a binding affinity of 6.7 ± 1.7 nM for PSMA and an exceptionally high internalization ratio (67% ± 13%) in vitro. In organ distribution studies, high and specific tumor uptake (8.0 ± 2.4 percentage injected dose per gram) in LNCaP tumor-bearing mice was observed. In the small-animal PET experiments, LNCaP tumors were clearly visualized. Conclusion: The radiofluorinated PSMA ligand showed promising characteristics in its preclinical evaluation, and the feasibility of prostate cancer imaging was demonstrated by small-animal PET studies. Therefore, we recommend clinical transfer of the radioligand 18F-PSMA-1007 for use as a diagnostic PET tracer in prestaging and monitoring of prostate cancer. | ||
| 534 | |c 2016 | ||
| 650 | 4 | |a 18F | |
| 650 | 4 | |a PET | |
| 650 | 4 | |a prostate cancer | |
| 650 | 4 | |a PSMA | |
| 700 | 1 | |a Leotta, Karin |e VerfasserIn |0 (DE-588)1068657669 |0 (DE-627)82057404X |0 (DE-576)427989345 |4 aut | |
| 700 | 1 | |a Haberkorn, Uwe |d 1959- |e VerfasserIn |0 (DE-588)1022913905 |0 (DE-627)717331245 |0 (DE-576)366166352 |4 aut | |
| 700 | 1 | |a Giesel, Frederik L. |d 1970- |e VerfasserIn |0 (DE-588)129031240 |0 (DE-627)387883878 |0 (DE-576)297457071 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of nuclear medicine |d New York, NY : Soc., 1964 |g 58(2017), 3, Seite 425-431 |h Online-Ressource |w (DE-627)325793603 |w (DE-600)2040222-3 |w (DE-576)09475277X |x 2159-662X |7 nnas |a Preclinical evaluation of 18F-PSMA-1007, a new prostate-specific membrane antigen ligand for prostate cancer imaging |
| 773 | 1 | 8 | |g volume:58 |g year:2017 |g number:3 |g pages:425-431 |g extent:7 |a Preclinical evaluation of 18F-PSMA-1007, a new prostate-specific membrane antigen ligand for prostate cancer imaging |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2967/jnumed.116.181768 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u http://jnm.snmjournals.org/content/58/3/425 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180423 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 129031240 |a Giesel, Frederik L. |m 129031240:Giesel, Frederik L. |d 910000 |d 911400 |e 910000PG129031240 |e 911400PG129031240 |k 0/910000/ |k 1/910000/911400/ |p 9 | ||
| 998 | |g 1022913905 |a Haberkorn, Uwe |m 1022913905:Haberkorn, Uwe |d 910000 |d 911400 |e 910000PH1022913905 |e 911400PH1022913905 |k 0/910000/ |k 1/910000/911400/ |p 8 | ||
| 998 | |g 1068657669 |a Leotta, Karin |m 1068657669:Leotta, Karin |d 910000 |d 911400 |e 910000PL1068657669 |e 911400PL1068657669 |k 0/910000/ |k 1/910000/911400/ |p 5 | ||
| 999 | |a KXP-PPN1572238658 |e 3006756428 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Published online: October 27, 2016","Gesehen am 23.04.2018"],"recId":"1572238658","person":[{"role":"aut","family":"Cardinale","given":"Jens","display":"Cardinale, Jens"},{"given":"Karin","display":"Leotta, Karin","family":"Leotta","role":"aut"},{"role":"aut","family":"Haberkorn","display":"Haberkorn, Uwe","given":"Uwe"},{"role":"aut","family":"Giesel","given":"Frederik L.","display":"Giesel, Frederik L."}],"language":["eng"],"name":{"displayForm":["Jens Cardinale, Martin Schäfer, Martina Benešová, Ulrike Bauder-Wüst, Karin Leotta, Matthias Eder, Oliver C. Neels, Uwe Haberkorn, Frederik L. Giesel, Klaus Kopka"]},"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"2017"}],"relHost":[{"title":[{"subtitle":"JNM","title":"Journal of nuclear medicine","title_sort":"Journal of nuclear medicine"}],"id":{"eki":["325793603"],"issn":["2159-662X","1535-5667"],"zdb":["2040222-3"]},"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedDisp":"1964-","publisher":"Soc.","publisherPlace":"New York, NY","dateIssuedKey":"1964"}],"name":{"displayForm":["Society of Nuclear Medicine"]},"recId":"325793603","type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"Preclinical evaluation of 18F-PSMA-1007, a new prostate-specific membrane antigen ligand for prostate cancer imagingJournal of nuclear medicine","corporate":[{"display":"Society of Nuclear Medicine","role":"isb"}],"titleAlt":[{"title":"JNM"}],"language":["eng"],"part":{"volume":"58","year":"2017","text":"58(2017), 3, Seite 425-431","pages":"425-431","extent":"7","issue":"3"},"pubHistory":["Nachgewiesen 5.1964 -"],"note":["Gesehen am 13.12.2021"]}],"physDesc":[{"extent":"7 S."}],"id":{"doi":["10.2967/jnumed.116.181768"],"eki":["1572238658"]},"title":[{"title":"Preclinical evaluation of 18F-PSMA-1007, a new prostate-specific membrane antigen ligand for prostate cancer imaging","title_sort":"Preclinical evaluation of 18F-PSMA-1007, a new prostate-specific membrane antigen ligand for prostate cancer imaging"}],"type":{"media":"Online-Ressource","bibl":"article-journal"}} | ||
| SRT | |a CARDINALEJPRECLINICA2017 | ||